Evidence map›Paper›PMID 9794789›Full record

ArticleThe Biochemical journal1998

Roles of the N- and C-terminal domains of carnitine palmitoyltransferase I isoforms in malonyl-CoA sensitivity of the enzymes: insights from expression of chimaeric proteins and mutation of conserved histidine residues.

S T Swanson, D W Foster, J D McGarry, N F Brown

Open access · bronzeAbstract read
In one paragraph

Article in The Biochemical journal, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
6.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 56 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. C75 increases peripheral energy utilization and fatty acid oxidation in diet-induced obesity.Proceedings of the National Academy of Sciences of the United States of America · 2002
    Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

S T SwansonDepartment of Internal Medicine, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75235-9135, USA.
D W Foster
J D McGarry
N F Brown
The University of Texas Southwestern Medical Center · US

Funding

REGULATION OF GLUCOSE AND FATTY ACID METABOLISMR01DK018573 · NIDDK · UNIVERSITY OF TEXAS SW MED CTR/DALLAS · PI FOSTER, DANIEL W · 1986 to 2002
$1.2M
CARNITINE PALMITOYLTRANSFERASE AND FATTY ACID METABOLISMR37DK018573 · NIDDK · UNIVERSITY OF TEXAS SW MED CTR/DALLAS · PI FOSTER, DANIEL W · 1990 to 1997
–
NIDDK NIH HHS DK18573
6 · The paper itself

Abstract

The mitochondrial outer membrane enzyme carnitine palmitoyltransferase I (CPT I) plays a major role in the regulation of fatty acid entry into the mitochondrial matrix for beta-oxidation by virtue of its inhibition by malonyl-CoA. Two isoforms of CPT I, the liver type (L) and muscle type (M), have been identified, the latter being 100 times more sensitive to malonyl-CoA and having a much higher Km for the substrate carnitine. Here we have examined the roles of different regions of the CPT I molecules in their response to malonyl-CoA, etomoxir (an irreversible inhibitor) and carnitine. To this end, we analysed the properties of engineered rat CPT I constructs in which (a) the N-terminal domain of L-CPT I was deleted, (b) the N-terminal domains of L- and M-CPT I were switched, or (c) each of three conserved histidine residues located towards the N-terminus in L-CPT I was mutated. Several novel points emerged: (1) whereas the N-terminal domain is critical for a normal malonyl-CoA response, it does not itself account for the widely disparate sensitivities of the liver and muscle enzymes to the inhibitor; (2) His-5 and/or His-140 probably play a direct role in the malonyl-CoA response, but His-133 does not; (3) the truncated, chimaeric and point- mutant variants of the enzyme all bound the covalent, active-site- directed ligand, etomoxir; and (4) only the most radical alteration of L-CPT I, i.e. deletion of the N-terminal 82 residues, affected the response to carnitine. We conclude that the N-terminal domain of CPT I plays an essential, but permissive, role in the inhibition of the enzyme by malonyl-CoA. By contrast, the larger C-terminal region dictates the degree of sensitivity to malonyl-CoA, as well as the response to carnitine; it is also sufficient for etomoxir binding. Additionally, further weight is added to the notion that one or more histidine residues may be involved in the CPT I-malonyl-CoA interaction.

Indexed as

HistidineAmino Acid SequenceAmino Acid SubstitutionAnimalsCarnitine O-PalmitoyltransferaseConserved SequenceCOS CellsEpoxy CompoundsIsoenzymesKineticsMalonyl Coenzyme AMutagenesis, Site-DirectedPeptide FragmentsPoint MutationRatsRecombinant Fusion ProteinsCarnitine O-PalmitoyltransferaseEpoxy CompoundsetomoxirHistidineIsoenzymesMalonyl Coenzyme APeptide FragmentsRecombinant Fusion Proteins

Identifiers

PMID9794789
PMCPMC1219810
OpenAlexW2234558981

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.